SCHEMBL7306225

SCHEMBL7306225

CCCc1nc2c(C)cc(N3CCCCC3=O)cc2n1Cc1ccc(-c2ccccc2-c2nnn(C(c3ccccc3)(c3ccccc3)c3ccccc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ AGTR1 P30556 14/20 0.50
▸ AGTR2 P50052 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9754859 0.82 PPARG (0.60) AGTR1AGTR2
SCHEMBL7312115 0.81 AGTR1 (0.49) AGTR1AGTR2
SCHEMBL7313039 0.81 PPARG (0.56) AGTR1AGTR2
SCHEMBL8848164 0.80 AGTR1 (0.47) AGTR1AGTR2
SCHEMBL8848377 0.80 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL8847745 0.80 AGTR1 (0.47) AGTR1AGTR2
SCHEMBL8847462 0.79 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL8848252 0.79 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL8848066 0.78 AGTR1 (0.46) AGTR1AGTR2
SCHEMBL8847565 0.78 AGTR1 (0.46) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0502314-B1 Benzimidazol derivatives, medicaments containing them and process for their preparation THOMAE GMBH DR K (DE) 1998-05-20 — — EP disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 — — US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 — — US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 — — US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 — — US disclosed
Send feedback